To the Editor: Gruen and colleagues1 have not accurately represented the current safety data on the risk of vascular occlusive events (VOE) with tranexamic acid (TxA), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.